INTRAPERITONEAL (IP) RADIOIMMUNOTHERAPY WITH I-131-LABELLED AND Y-90-LABELED MONOCLONAL-ANTIBODIES

被引：0
|
作者：
STEWART, JSW [1 ]
HIRD, V [1 ]
EPENETOS, AA [1 ]
机构：
[1] HAMMERSMITH HOSP,IMPERIAL CANC RES FUND GRP,LONDON W12 0HS,ENGLAND
来源：
BRITISH JOURNAL OF CANCER | 1989年 / 59卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：313 / 313
页数：1
相关论文
共 50 条
  • [31] COMPARISON OF THE DISTRIBUTION AND BINDING OF MONOCLONAL-ANTIBODIES LABELED WITH I-131 OR IN-111
    BUCHSBAUM, D
    RANDALL, B
    HANNA, D
    CHANDLER, R
    LOKEN, M
    JOHNSON, E
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1985, 10 (9-10): : 398 - 402
  • [32] TUMOR-IMMUNOTHERAPY IN THE MOUSE WITH THE USE OF I-131-LABELED MONOCLONAL-ANTIBODIES
    ZALCBERG, JR
    THOMPSON, CH
    LICHTENSTEIN, M
    MCKENZIE, IFC
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1984, 72 (03) : 697 - 704
  • [33] TREATMENT OF HUMAN-TUMOR XENOGRAFTS WITH I-131-LABELED MONOCLONAL-ANTIBODIES
    SENEKOWITSCH, R
    GLASSNER, H
    REIDEL, G
    MOLLENSTADT, G
    KRIEGEL, H
    PABST, HW
    BRITISH JOURNAL OF CANCER, 1987, 56 (04) : 517 - 517
  • [34] INTRALESIONAL ADMINISTRATION OF I-131-LABELED MONOCLONAL-ANTIBODIES IN THE TREATMENT OF MALIGNANT GLIOMAS
    ARISTA, A
    STURIALE, C
    RIVA, P
    TISON, V
    FRATTARELLI, M
    MOSCATELLI, G
    FRANCESCHI, G
    SPINELLI, A
    ACTA NEUROCHIRURGICA, 1995, 135 (3-4) : 159 - 162
  • [35] I-131 and Y-90 labelled antitenascin MAbs locoregionally infused for the radioimmunotherapy of glioblastoma.
    Riva, P
    Arista, A
    Franceschi, G
    Cremonini, AM
    Riva, N
    Casi, M
    Giuliani, G
    Gentile, R
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 216 - 216
  • [36] Combined Radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with Taxol
    Crow, DM
    Williams, L
    Colcher, D
    Wong, JYC
    Raubitschek, A
    Shively, JE
    BIOCONJUGATE CHEMISTRY, 2005, 16 (05) : 1117 - 1125
  • [37] Complete versus fragmented, I-131- and Y-90-labeled antibodies for radioimmunotherapy (RAIT) of CEA-expressing cancers: Influence of dose rate and renal accretion on toxicity and anti-tumor-efficacy.
    Behr, TM
    Memtsoudis, S
    Blumenthal, RD
    Dunn, RM
    Sharkey, RM
    Goldenberg, DM
    Becker, W
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 107 - 107
  • [38] PRECLINICAL ASSESSMENT OF Y-90-LABELED MONOCLONAL-ANTIBODY CO17-1A, A POTENTIAL AGENT FOR RADIOIMMUNOTHERAPY OF COLORECTAL-CARCINOMA
    WASHBURN, LC
    LEE, YCC
    SUN, TTH
    BYRD, B
    CROOK, JE
    STABIN, MG
    STEPLEWSKI, Z
    NUCLEAR MEDICINE AND BIOLOGY, 1988, 15 (06): : 707 - 711
  • [39] RADIOIMMUNOSCINTIGRAPHY OF GYNECOLOGIC TUMORS WITH I-131-LABELED ANTI-PLAP MONOCLONAL-ANTIBODIES
    RIKLUND, KE
    EDBOM, G
    MAKIYA, R
    JOHANSSON, B
    GERDES, U
    HIETALA, SO
    EKELUND, L
    STIGBRAND, T
    STENDAHL, U
    ACTA RADIOLOGICA, 1991, 32 (05) : 375 - 380
  • [40] I-131-LABELED MONOCLONAL-ANTIBODIES AS A PREPARATIVE REGIMEN FOR MARROW TRANSPLANTATION - INITIAL DOSIMETRY
    APPELBAUM, FR
    BADGER, C
    NELP, WB
    BROWN, P
    DEEG, HJ
    SCHUNING, F
    STORB, R
    EXPERIMENTAL HEMATOLOGY, 1986, 14 (06) : 456 - 456
12345